– USA, MA – Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Dr. Steve Mayo, (Ph.D.) to its Board of Directors, effective immediately.
Dr. Mayo is currently the Bren Professor of Biology and Chemistry at California Institute of Technology and serves on the board of directors for Merck and the scientific advisory board of Rubryc Therapeutics.
“We are delighted to welcome Dr. Mayo to the Sarepta Board of Directors. A world-renowned expert in protein engineering, he will bring significant scientific and business acumen to our board as Sarepta advances its industry leading pipeline of genetic medicines,” said Board Chair, Dr. Kathleen Behrens.
“A trailblazer in science and academia, Dr. Mayo’s impressive track record of scientific achievement and business success will be vital as we work to deliver on the promise of our pipeline and change the model for treating individuals with rare disease,” added CEO, Doug Ingram.
About Dr. Stephen L. Mayo
At Caltech, Dr. Mayo holds joint appointments in the Division of Biology and Biological Engineering and the Division of Chemistry and Chemical Engineering. He joined the Caltech faculty in 1992 and served as Vice Provost for Research from 2007 to 2010 and Chair of the Division of Biology and Biological Engineering from 2010 to 2020. Dr. Mayo’s research focuses on the development of computational approaches to protein engineering – a field that has broad applications ranging from advanced biofuels to human therapeutics. In 2004, he was elected to the U.S. National Academy of Sciences for his pioneering contributions in the field of protein design.
Dr. Mayo has co-founded several companies: Molecular Simulations Inc. (now Biovia), Xencor, and Protabit, where he serves on the scientific advisory board. In addition to his academic and private-sector work, Dr. Mayo has served as an elected Board Member at the American Association for the Advancement of Science (2010-2014) and served as a presidential appointee to National Science Foundation’s National Science Board (2013-2018).
“Sarepta is at the forefront of a transformative era in genetic medicine and their multi-platform approach across RNA, gene therapy, and gene editing is particularly exciting. It is an honor to join the board at this pivotal juncture,” said Dr. Mayo. “I look forward to working with the Sarepta team and contributing in a meaningful way to the Company’s mission, growth, and continued success on behalf of patients.”
Dr. Mayo received an undergraduate degree in chemistry from the Pennsylvania State University and a Ph.D. from Caltech. He completed postdoctoral work at both UC Berkeley and the Stanford University School of Medicine.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy and limb-girdle muscular dystrophies, and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing.
For more information: https://www.sarepta.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.